Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-35 (Canceled)

36. (Previously presented) A non-human transgenic mammal, which comprises an IgH locus modified by replacing a switch sequence Sμ with all or part of a transgene consisting of a Cα gene for a human class A immunoglobulin, comprising at least an exon encoding the CH3 domain and a membrane exon.

37. (Previously presented) The non-human transgenic mammal of claim 36, which is homozygous for said modified IgH locus.

38. (Previously presented) The non-human transgenic mammal of claim 36, wherein said IgH locus is modified by replacing the switch sequence Sμ, with the entire Cα gene.

39. (Previously presented) The non-human transgenic mammal of claim 36, wherein IgH locus is modified by replacing the switch sequence Sμ with the segment of the Cα gene comprising the exon encoding the CH3 domain and the membrane exon.

40. (Previously presented) The non-human transgenic mammal of claim 36, wherein said Ca gene is Cα1.

41. (Previously presented) The non-human transgenic mammal of claim 36, which further comprises another transgene encoding a human immunoglobulin light chain.

42. (Previously presented) The non-human transgenic mammal of claim 41, wherein said light chain is a kappa chain.

43. (Previously presented) The non-human transgenic mammal of claim 42, wherein said transgene comprises the intronic activator Eμ upstream and the palindrome *hs3a/hs1,2/hs3b* downstream.

44. (Previously presented) The non-human transgenic mammal of claim 43, wherein said transgene is under the control of the promoter of the human immunoglobulin heavy chain.

45. (Previously presented) The non-human transgenic mammal of claim 41, which is dizygous for said transgene.

46. (Previously presented) The non-human transgenic mammal of claim 41, which possesses an endogenous locus of the inactivated kappa chain.

47. (Previously presented) The non-human transgenic mammal of claim 46, which is homozygous for said endogenous locus of the inactivated kappa gene.

48. (Previously presented) The non-human transgenic mammal of claim 36, which possesses a gene encoding the inactivated J chain.

49. (Previously presented) The non-human transgenic mammal of claim 48, which is homozygous for said gene encoding the inactivated J chain.

50. (Previously presented) The non-human transgenic mammal of claim 48, which comprises another transgene encoding a human immunoglobulin J gene.

51. (Previously presented) The non-human transgenic mammal of claim 36, which is a transgenic mouse.

52. (Previously presented) A transgenic mouse of claim 51, which comprises:

a) an IgH locus modified by replacing the switch sequence Sμ with the entire Cα1 gene for a human class A immunoglobulin, and

b) a complete Vκ gene comprising rearranged VκI gene with a Jκ5 gene, the Jκ-Cκ intron and Cκ gene, under the transcriptional control of the promoter of the human heavy chain (pVH), the intronic activator Eμ upstream and the palindrome *hs3a/hs1,2/hs3b* downstream.

53. (Previously presented) A homologous recombination targeting vector, which comprises a Cα gene for a human class A immunoglobulin or a segment of the gene comprising at least an exon encoding a CH3 domain and a membrane exon, flanked by fragments of sequences of the IgH locus from a non-human mammal which are adjacent to a Sμ sequence.

54. (Previously presented) The targeting vector of claim 53, which comprises a cassette for expressing a selection marker, adjacent to said Cα gene or to a segment of said gene.

55. (Previously presented) The targeting vector of claim 54, wherein said expression cassette is flanked by site-specific recombination sequences.

56. (Previously presented) The targeting vector of claim 54, wherein sequences are LoxP sequences of Cre recombinase.

57. (Previously presented) The targeting vector of claim 53, wherein said fragments of sequences which are adjacent to the Su sequence are of murine origin.

58. (Currently amended) The targeting vector of claim 56, wherein the Cα gene or the segment of said gene is flanked, in 5' and in 3' respectively, by ~~fragments corresponding to positions 131281 to 136441 and 140101 to 145032 in the sequence of murine chromosome 12 (accession number AC073553 in the EMBL/Genbank database)~~ said fragments consisting of the sequences SEQ ID NO:7 and SEQ ID NO:8 corresponding respectively to positions 131281 to 136441 and 140101 to 145032 in the sequence of murine chromesome 12 (accession number AC073553 in the EMBL/GenBank database).

59. (Previously presented) An embryonic cell of a non-human mammal, modified with the targeting vector of claim 53.

60. (Previously presented) A method for preparing humanized class IgA antibodies or fragments thereof, which comprises at least the following steps:

a) immunizing a non-human transgenic mammal of claim 36, and,

b) producing humanized class IgA antibodies or fragments of the antibodies from serum, secretions or B lymphocytes of said non-human transgenic mammal sacrificed beforehand.

61. (Previously presented) The method of claim 60, wherein the non-human transgenic mammal is a transgenic mouse.

62. (Previously presented) A humanized class IgA antibody produced by the method if claim 60, which comprises a chimeric heavy chain in which the constant domains are of human origin and a human light chain in which the variable domain is encoded by VκI-Jκ5.

63. (Previously presented) A fragment of a humanized class IgA antibody of claim 62, which comprises a fragment of said heavy and light chains.

64. (Previously presented) The humanized class IgA antibody fragment of claim 63, which is selected from the group consisting of the Fab, Fab'2 and Fc fragments.

65. (Previously presented) A medicament, which comprises a humanized class IgA antibody of claim 62, or a fragment of the antibody of claim 63.

66. (Previously presented) A diagnostic reagent, which comprises a humanized class IgA antibody of claim 62, or a fragment of the antibody of claim 63.

67. (Previously presented) An immunogenic or vaccine composition, which comprises at least one humanized class IgA antibody of claim 62, or a fragment of the antibody of claim 63, combined with an antigen.

68. (Previously presented) A pharmaceutical composition, which comprises at least one humanized class IgA antibody of claim 62, or a fragment of the antibody of claim 63; with an active ingredient.

69. (Previously presented) A method of preparing a reagent, which comprises combining at least one humanized class IgA antibody of claim 62, or a fragment thereof of claim 63, with an active ingredient.

70. (Previously presented) A method of treating infectious diseases or cancer, which comprises administering at least one humanized class IgA antibody of claim 62, or a fragment thereof of claim 63, to a mammal in need thereof.

71. (Previously presented) The method of claim 70, wherein the mammal is a human.

72. (Previously presented) The method of claim 70, for treating infectious diseases.

73. (Previously presented) The method of claim 70, for treating cancer.